Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL - Archive ouverte HAL Access content directly
Journal Articles Best Practice and Research: Clinical Haematology Year : 2011

Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL

(1) , (1, 2)
1
2

Abstract

High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment.
Not file

Dates and versions

ensl-00808492 , version 1 (05-04-2013)

Identifiers

  • HAL Id : ensl-00808492 , version 1

Cite

Emmanuel Bachy, Gilles Salles. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Practice and Research: Clinical Haematology, 2011, 24 (2), pp.257-270. ⟨ensl-00808492⟩
55 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More